Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory study of geranylgeranylacetone (teprenone) in heart failure
jRCTs031220395Completed
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of teprenone in heart failure (HF) (2 arms). Primary endpoints: Change in NT-proBNP at 24 weeks and Change in CK-MB and troponin at 24 weeks. Started Oct 2022; status: completed.
02
Drugs
teprenone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on jRCTs031220395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220395.